Fosamprenavir Side Effects
Medically reviewed by Drugs.com. Last updated on Mar 16, 2023.
Applies to fosamprenavir: oral suspension, oral tablet.
Serious side effects of Fosamprenavir
Along with its needed effects, fosamprenavir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking fosamprenavir:
- Black, tarry stools
- lower back or side pain
- painful or difficult urination
- pale skin
- skin rash
- sore throat
- ulcers, sores, or white spots in the mouth
- unusual bleeding or bruising
- unusual tiredness or weakness
Incidence not known
- Blistering, peeling, loosening of the skin
- blood in the urine
- chest pain or discomfort
- joint or muscle pain
- large amount of cholesterol in the blood
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
- pain in the groin or genitals
- pain or discomfort in the arms, jaw, back, or neck
- red skin lesions, often with a purple center
- red, irritated eyes
- sharp back pain just below the ribs
Other side effects of Fosamprenavir
Some side effects of fosamprenavir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- stomach pain
Incidence not known
- Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings in the mouth
For Healthcare Professionals
Applies to fosamprenavir: oral suspension, oral tablet.
Diarrhea, rash, nausea, vomiting, and headache were the most frequent moderate to severe side effects in clinical trials. Discontinuations due to side effects were 6.4% in patients using this drug compared to 5.9% in those using comparator therapies; the most common side effects leading to discontinuation of this drug (incidence up to 1%) included diarrhea, nausea, vomiting, increased AST, increased ALT, and rash.[Ref]
Skin rash (regardless of causality) was reported in about 19% of patients. Rashes were generally maculopapular and of mild or moderate intensity, some with pruritus. Rash had a median onset and duration of 11 and 13 days, respectively, and led to discontinuation of this drug in less than 1% of patients.[Ref]
Very common (10% or more): Skin rash (up to 19%)
Common (1% to 10%): Rash/cutaneous reactions (including erythematous or maculopapular cutaneous eruptions [with or without pruritus])
Rare (0.01% to 0.1%): Severe and/or life-threatening skin reactions (including Stevens-Johnson syndrome)
Frequency not reported: Erythema multiforme, pruritus
Postmarketing reports: Angioedema
-Frequency not reported: Lipohypertrophy[Ref]
Very common (10% or more): Diarrhea (up to 13%)
Common (1% to 10%): Nausea, vomiting, abdominal pain, increased serum lipase, loose stools, gastritis, abdominal distension, upper abdominal pain, flatulence
Uncommon (0.1% to 1%): Gastroesophageal reflux disease
Frequency not reported: Increased amylase
Postmarketing reports: Oral paresthesia[Ref]
Increased serum lipase (greater than 2 times the upper limit of normal [2 x ULN]) has been reported in up to 8% of patients.
Vomiting was reported more often in pediatric patients than adult patients.[Ref]
Increased fasting triglycerides (greater than 750 mg/dL) have been reported in up to 11% of patients.[Ref]
Very common (10% or more): Increased fasting triglycerides (up to 11%)
Common (1% to 10%): Fatigue
Uncommon (0.1% to 1%): Pyrexia, increased cholesterol
-Frequency not reported: Increased weight, increased blood lipids[Ref]
Common (1% to 10%): Elevated ALT, elevated AST
Frequency not reported: Liver toxicity[Ref]
Elevated ALT (greater than 5 x ULN) and AST (greater than 5 x ULN) have been reported in up to 8% and up to 6% of patients, respectively.[Ref]
Decreased absolute neutrophil count (less than 750 cells/mm3) has been reported in 3% of patients.
Common (1% to 10%): Decreased absolute neutrophil count, neutropenia
-Frequency not reported: Acute hemolytic anemia
Increased glucose (greater than 251 mg/dL) has been reported in 2% of patients.[Ref]
Common (1% to 10%): Increased glucose, hyperlipidemia, hypertriglyceridemia
Uncommon (0.1% to 1%): Anorexia
Frequency not reported: Hyperglycemia, increased body fat
Postmarketing reports: Hypercholesterolemia
-Frequency not reported: Hypertriglyceridemia, hypercholesterolemia, resistance to insulin
-Frequency not reported: Increased glucose[Ref]
Common (1% to 10%): Headache, dizziness[Ref]
Common (1% to 10%): Drug hypersensitivity[Ref]
Postmarketing reports: Myocardial infarction[Ref]
Frequency not reported: Elevated creatine kinase, osteonecrosis
-Rare (0.01% to 0.1%): Rhabdomyolysis
-Frequency not reported: Increased creatine phosphokinase, myalgia, myositis[Ref]
Frequency not reported: Depressive/mood disorders[Ref]
More about fosamprenavir
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- Drug class: protease inhibitors
- En español
Related treatment guides
1. Warnke D, Barreto J, Temesgen Z. Antiretroviral drugs. J Clin Pharmacol. 2007;47:1570-9.
2. Drugs for HIV infection. Treat Guidel Med Lett. 2009;7:11-22.
3. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. https://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf 2018.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf 2018.
5. Product Information. Lexiva (fosamprenavir). GlaxoSmithKline. 2003.
6. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18:1529-1537.
7. Shelton MJ, Wire MB, Lou Y, Adamkiewicz B, Min SS. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob Agents Chemother. 2006;50:928-34.
8. Wire MB, Baker KL, Jones LS, et al. Ritonavir Increases Plasma Amprenavir (APV) Exposure to a Similar Extent when Coadministered with either Fosamprenavir or APV. Antimicrob Agents Chemother. 2006;50:1578-80.
9. Hester EK, Chandler HV, Sims KM. Fosamprenavir: drug development for adherence. Ann Pharmacother. 2006;40:1301-10.
10. Piacenti FJ. An update and review of antiretroviral therapy. Pharmacotherapy. 2006;26:1111-33.
11. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-82.
12. Ruane PJ, Luber AD, Wire MB, et al. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams fosamprenavir once daily in combination with either 100 OR 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother. 2006;51:560-5.
13. Pavel S, Burty C, Alcaraz I, et al. Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen. AIDS. 2007;21:268-269.
14. Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008;62:879-88.
15. Arvieux C, Tribut O. Amprenavir or Fosamprenavir plus Ritonavir in HIV Infection: Pharmacology, Efficacy and Tolerability Profile. Drugs. 2005;65:633-59.
16. Gathe JC Jr, Wood R, Sanne I, et al. Long-Term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: An uncontrolled, open-label, single-arm follow-on study. Clin Ther. 2006;28:745-54.
17. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073-89.
18. Bergersen BM. Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy. Drugs. 2006;66:1971-87.
19. Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS. 2010;24:789-802.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.